Menu
Recruiting NCT06847932

Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development

No phase Interventional Atrial Fibrillation (AF) Premature Atrial Complexes Atrial Arrhythmias Artificial Intelligence (AI)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: AF-predict AI-ECG alert system guided management.
Who it may be relevant to
Registry conditions: Atrial Fibrillation (AF), Premature Atrial Complexes, Atrial Arrhythmias, Artificial Intelligence (AI). Basic parameters: 40 Days — 85 Days · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Taiwan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Leveraging AI-ECG Technology for Early Notification and Tracking of AF Development: a Randomized Control Trial

Overview

Our study aimed to use an AF-predict AI-ECG alert system to help physicians identify patients who need to wear a continuous cardiac rhythm monitor for new diagnoses of atrial fibrillation (AF), atrial flutter (AFL), or atrial arrhythmia with high AF risk, including premature atrial complexes (PAC) ≥ 500/24hr, burst PACs \> 20 beats, non-sustained AF/AFL.

Interventions

  • Other AF-predict AI-ECG alert system guided management
    AF-predict AI-ECG alert system

Primary outcome measures

  • Latent atrial fibrillation [Time frame: Within 90 days after enrollment.]
Secondary outcome measures (3)
  • Antiarrhythmic treatment [Time frame: Within 180 days after enrollment.]
  • 90-days New diagnoses of atrial fibrillation/atrial flutter [Time frame: Within 90 days after enrollment.]
  • Atrial arrhythmia with high AF risk [Time frame: Within 90 days after enrollment.]

Eligibility criteria

Inclusion criteria

  • Patients in the inpatient department or the outpatient department
  • Patients need to have at least one electrocardiogram within one year

Exclusion criteria

  • Diagnosis of atrial fibrillation/atrial flutter
  • History of atrial fibrillation/atrial flutter catheter ablation
  • Patients with cardiac implantable electronic devices
  • Any documented electrocardiogram showed atrial fibrillation/atrial flutter and pacing rhythm
  • History of received rhythm control medications for atrial arrhythmia, including Class I and Class III antiarrhythmic drugs
  • Any reasons indicate for anti-coagulant agents, including vitamin K antagonist and non-vitamin K antagonist oral anticoagulant

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Diagnostic

Study locations

Taiwan · 1 center
  • Tri-Service General Hospital — Taipei

Identifiers

NCT: NCT06847932 · A202205179

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗